This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study was a randomised controlled trial, based at 3 centres: Durham, North Carolina, USA, Michigan, USA and Buenos Aires, Argentina. Randomisation was carried out using a computer-generated schedule and stratified according to surgeon to ensure an even distribution of groups among surgeons. All clinicians and investigators were blinded to treatment allocation, with drugs administered in equal volumes. Patients received a 1 mg blinded test dose of the study drug before surgery to check for allergy. Blinding was broken in 4 patients, 2 in each group, during surgery because of clinicians' concerns over level of bleeding. These were included in final analysis, but did not affect the statistical significance of results. Duration of follow up was not specified.
Analysis of effectiveness
The analysis was based on intention to treat. The primary health outcome was the 24 hour postoperative volume of thoracic drainage. The number of allogeneic blood product transfusions, the number of donor exposures, duration of chest closure, and the surgical assessment of "dryness" of surgical field, were also estimated. Groups were demonstrated to be comparable in terms of demographic factors, preoperative medical condition and intra-operative characteristics.
Effectiveness results
Results are expressed as medians, with the 25th and 75th percentiles given in brackets. The 24 hour postoperative volume of thoracic drainage (unit of measurement not specified) was 511 (383 -805) in the aprotinin group and 655 (464 -1045) in the EACA group, (p=0.016). The only statistically significant difference detected between the number of allogeneic blood product transfusions received by the two groups, was that the aprotinin group received significantly fewer platelets (p=0.036). The number of donor exposures was 2 (0 -7) in the aprotinin group and 3 (1 -13) in the EACA group, (p=0.084). The duration of chest closure was 50 minutes (40 -69) in the aprotinin group and 54 minutes (42 -67) in the EACA group, (p=0.439). The surgeon considered the field "dry" in 44% of cases in the aprotinin group and 26% in the EACA group, (p=0.012).
Clinical conclusions
Aprotinin therapy was more effective than EACA therapy at reducing bleeding associated with repeated cardiac surgery.
Measure of benefits used in the economic analysis
The number of donor exposures was the measure of benefit the authors considered relevant for the economic study and, because the differences were insignificant, the economic analysis was based on costs only.
